Collegium Completes $650M AZSTARYS Acquisition, Raises 2026 Revenue Guidance to $865M-$895M
summarizeSummary
Collegium Pharmaceutical has completed its previously announced $650 million acquisition of AZSTARYS from Corium Therapeutics, a central nervous system stimulant for ADHD. This follows the company's Q1 2026 10-Q filing on May 7, which detailed the acquisition and stated it was expected to close in Q2 2026, along with an intention to update guidance. The acquisition, funded by $350 million cash and $300 million from a credit facility, is highly material and significantly expands Collegium's ADHD portfolio with patent protection through 2037. Crucially, Collegium has raised its full-year 2026 financial guidance, with total product revenues now expected between $865 million and $895 million (up from $805-$825 million) and Adjusted EBITDA between $475 million and $500 million (up from $455-$475 million), indicating immediate accretion. The company also announced the departures of its Chief Commercial Officer and Chief Medical Officer, which will require monitoring for leadership transition.
At the time of this announcement, COLL was trading at $35.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $27.84 to $50.79. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.